VANCOUVER, March 2 /PRNewswire/ - iCo Therapeutics Inc. announced today
that Dr. Alan Bird has joined iCo's Strategic Advisory Team. A pioneer in
ophthalmic research, teaching and clinical medicine, Dr. Bird's contributions
to the field of retinal disease have met with worldwide acclaim.
"We are thrilled to have such a respected advisor on our team," said
Andrew Rae, iCo President and CEO. "His knowledge and experience will be
invaluable as we continue to seek out and license cutting-edge products to
build our ophthalmology portfolio."
Dr. Bird's esteemed career began at Moorfield's Eye Hospital in London,
England where his contributions to the treatment of retinal vascular disease
and genetic & degenerative retinal disorders were at the forefront of the
field. From Moorfield's, his academic career took him to the Bascom Palmer Eye
Institute and Jules Stein Eye Center in the United States. He returned to
London and spent the majority of his career at the Institute of Ophthalmology
at University College London and Moorfield's Eye Hospital where, in
collaboration with Professor Shomi Bhattacharya, Dr. Bird identified numerous
eye disease genes and cemented the standing of the University College London
and Moorfield's Eye Hospital as one of the top eye research and care centers
worldwide. Dr. Bird also spent time in Africa undertaking research into river
blindness, where his work led to the establishment of Ivermectin as the
treatment of choice for this disease.
Dr. Bird's expertise has been widely sought after and he has made
strategic contributions to the US National Eye Institute, the UK Medical
Research Council, the Wellcome Trust, INSERM and Deutsche
Forschungsgemeinschaft. He has also played a key role in the design and
evaluation of numerous clinical trials involving ground-breaking treatments in
retinal disease today. Most recently, Dr. Bird chaired the Independent Data
Safety and Monitoring Committee for the pegaptanib pivotal trial for
age-related macular degeneration.
"iCo's business model of developing pre-existing drugs for diseases of
the eye has significant potential," said Dr. Bird. "I look forward to helping
with the clinical trial design of these products, beginning with the antisense
compound iCo 007."
Dr. Bird is a Fellow of the UK National Academy of Medical Science and
has received a number of prestigious awards in vision science and
ophthalmology, including the Alcon Research Award, The Helen Keller Prize, the
Kayser Award, and the Jules Francois Medal. In 2006, he was honored with the
lifetime achievement award by the Macular Society.
iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
company focused on developing pre-existing drugs for a range of new conditions
affecting isolated biological environments - areas such as the eye, spinal
cord, or joints - where locally-administered application of these therapies
would have minimal systemic distribution and fewer safety issues.
For more information, visit the company website at
Business Development Contact: Finance/Investor Contact:
Dr. John Clement, CTO Mr. John Meekison, CFO
SOURCE iCo Therapeutics Inc.